Jump to content

Advancing Safety in Manufactured Human Cell Products: The Strategic Value of Next-Generation Sequencing

In this webinar, Tracie Fradet, Associate Director of Cytogenomics at the Astellas Institute for Regenerative Medicine (AIRM), discusses the implementation of NGS assays to ensure the biosafety of cell therapy products in a validated environment. Tracie outlines the effort of the Cytogenomics group in developing a GMP-compliant NGS workflow to comply with the evolving regulatory requirements. She emphasizes the value of Genedata Selector in facilitating the integration, analysis, and sharing of project-related data in a GMP environment, thereby improving decision-making and accelerating time to market. Tracie concludes her talk by sharing insights from the recent FDA Type D meeting held at AIRM, where the FDA expressed their alignment with AIRM’s NGS platform and validation approach.

This talk was given as part of our regular Open Forum events on NGS-based QC for advancing drug development and manufacturing. 


Who should watch? 

Biopharma and biotech professionals looking to advance analytical development, biosafety, and QC testing for CGT products by embracing digitalization and innovative enterprise data analysis systems. 


Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy